Zomedica Corp. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Zomedica Corp. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $4.13M | Mar 1, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.03M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $27.29M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $25.19M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $18.93M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.13M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $0 | Mar 1, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.68M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $19.09M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $17.32M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $13.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.05M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $0 | Mar 1, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($81.86M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($46.98M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($34.53M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($17.02M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($18.38M) | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | ($16.91M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($19.78M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($16.65M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($8.07M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($5.74M) | Feb 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.35M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($51.05M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($43.28M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($21.92M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($21.37M) | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | ($16.76M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($19.78M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($16.58M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($8.08M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($5.73M) | Feb 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.17M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $7.27M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $5.74M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.58M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.67M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $8.04M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $10.35M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $10.32M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $2.75M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $1.52M | Feb 28, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $33.00M | Mar 15, 2023 |
| FY2022 | Dec 31, 2021 | $22.76M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $8.72M | Mar 1, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.65M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($23.63M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($15.98M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($11.67M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($14.28M) | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | ($16.24M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($15.63M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($11.15M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($7.09M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($4.56M) | Feb 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $567.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $5.21M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $11.34M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $787.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $147.0K | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $14.9K | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $155.5K | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $628.0K | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $171.7K | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $231.6K | Feb 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.04M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $207.36M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $253.20M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $279.61M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $280.40M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $66.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $4.18M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $6.03M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $5.22M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | $4.58M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.64M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $11.70M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $13.18M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $12.22M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.51M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $3.12M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $2.09M | Feb 26, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.40M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $195.66M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $240.02M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $267.39M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $270.89M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $51.07M | Mar 15, 2023 |
| FY2022 | Dec 31, 2019 | $2.10M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $3.66M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $4.39M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.83M | Mar 14, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $45.56M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $61.58M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $63.98M | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $43.29M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $0 | Mar 1, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($299.77M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($217.92M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($170.93M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($136.40M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($119.39M) | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | ($68.97M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($52.06M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($32.27M) | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | ($15.63M) | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | ($7.56M) | Feb 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.02M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $7.02M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $12.95M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $27.40M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $194.95M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | $61.99M | Mar 1, 2022 |
| FY2022 | Dec 31, 2019 | $510.6K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.94M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $3.45M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $3.23M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $527.4K | Feb 26, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 979.95M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 979.95M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 979.95M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 979.95M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 979.90M | Mar 15, 2023 |
| FY2022 | Dec 31, 2020 | 642.04M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 108.04M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 97.60M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | 90.23M | Mar 14, 2019 |
| FY2017 | Dec 31, 2016 | 83.96M | Feb 28, 2018 |